Corporate ActionJun 25, 2026, 09:22 AM
Jaguar Health Converts Series O Preferred Stock to Common
AI Summary
Jaguar Health announced the automatic conversion of its Series O Convertible Preferred Stock into common stock at a ratio of 3.209 common shares per preferred share, effective June 25, 2026. This conversion follows the preferred stock being issued as a one-time special stock dividend. Additionally, the company's subsidiary, Napo Pharmaceuticals, amended its Manufacturing and Supply Agreement with Woodward Specialty LLC to clarify inventory management and transfer, ensuring business continuity. Jaguar Health also reiterated its focus on crofelemer development for rare intestinal failure diseases, targeting Breakthrough Therapy designation for MVID and an NDA filing in the first half of 2027.
Key Highlights
- Jaguar Health's Series O Convertible Preferred Stock automatically converted to common stock.
- Each preferred share converted into 3.209 shares of voting common stock.
- Cash will be paid for fractional common shares based on a $2.68 closing price.
- First Amendment to Manufacturing and Supply Agreement clarifies inventory transfer and management.
- Napo Pharmaceuticals will manage Woodward's inventory until Dec 31, 2026, or earlier.
- Jaguar Health targets Breakthrough Therapy designation for crofelemer for MVID.
- NDA filing for MVID indication with the FDA expected in the first half of 2027.
Price Impact
More from JAGX